cabozantinib,atezolizumab
roche
['contact 03', 'kidney cancer']
contact 03. the first randomized trial of rechallange io after progression on io in kidney cancer!
#asco23
many other tumor models should look at this data!
great presentation by 
Oncólogo Clínico staff @IAF_Fleming. Miembro @SelnetH2020 @aaoncoclinica. Interesado en #GUcsm. #clinicaltrials. #Immunotherapy #PrecisionMedicine #oncoalert